Biosimilars [Design Issues]

posted by Kumarnaidu2 – India, 2021-10-22 09:53 (518 d 21:46 ago) – Posting: # 22653
Views: 1,053

Dear All,

For a medicinal product to be administer as intravenous infusion (for approx. 3 hrs) if we consider Ctrough as one of the primary pk parameter for demonstrating PK similarity, does different rate of infusion amongst enrolled subjects has any impact on Ctrough levels?

Thanks in advance,


Complete thread:

UA Flag
 Admin contact
22,550 posts in 4,724 threads, 1,606 registered users;
14 visitors (0 registered, 14 guests [including 11 identified bots]).
Forum time: 06:40 CET (Europe/Vienna)

If there is an exception to any rule,
and if it can be proved by observation,
that rule is wrong.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz